190 related articles for article (PubMed ID: 32470439)
1. Molecular imaging in lymphoma beyond
Kahle XU; Montes de Jesus FM; Glaudemans AWJM; Lub-de Hooge MN; Jorritsma-Smit A; Plattel WJ; van Meerten T; Diepstra A; van den Berg A; Kwee TC; Noordzij W; de Vries EGE; Nijland M
Lancet Haematol; 2020 Jun; 7(6):e479-e489. PubMed ID: 32470439
[TBL] [Abstract][Full Text] [Related]
2. Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma.
Wright CL; Maly JJ; Zhang J; Knopp MV
PET Clin; 2017 Jan; 12(1):63-82. PubMed ID: 27863567
[TBL] [Abstract][Full Text] [Related]
3. Perspectives of molecular imaging and radioimmunotherapy in lymphoma.
Iagaru A; Goris ML; Gambhir SS
Radiol Clin North Am; 2008 Mar; 46(2):243-52, viii. PubMed ID: 18619379
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of therapy for lymphoma.
Jerusalem G; Hustinx R; Beguin Y; Fillet G
Semin Nucl Med; 2005 Jul; 35(3):186-96. PubMed ID: 16098292
[TBL] [Abstract][Full Text] [Related]
5. Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging.
Ayers EC; Fardin S; Gholami S; Alavi A; Mato AR
PET Clin; 2016 Jul; 11(3):209-18. PubMed ID: 27321026
[TBL] [Abstract][Full Text] [Related]
6. The role of FDG-PET imaging in the management of lymphoma.
Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ
Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171
[TBL] [Abstract][Full Text] [Related]
7. Molecular Imaging of Lymphoma: Future Directions and Perspectives.
Pomykala KL; Fendler WP; Vermesh O; Umutlu L; Herrmann K; Seifert R
Semin Nucl Med; 2023 May; 53(3):449-456. PubMed ID: 36344325
[TBL] [Abstract][Full Text] [Related]
8. Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.
Zukotynski KA; Kim CK
PET Clin; 2017 Oct; 12(4):393-405. PubMed ID: 28867111
[TBL] [Abstract][Full Text] [Related]
9. [F-18 fluorodeoxyglucose positron emission tomography in malignant lymphoma].
Mikosch P
Wien Med Wochenschr; 2002; 152(11-12):269-75. PubMed ID: 12138654
[TBL] [Abstract][Full Text] [Related]
10. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
11. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
12. When should FDG-PET be used in the modern management of lymphoma?
Barrington SF; Mikhaeel NG
Br J Haematol; 2014 Feb; 164(3):315-28. PubMed ID: 24131306
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG-PET in patients with malignant lymphoma having long-term follow-up: staging and restaging, and evaluation of treatment response and recurrence.
Isohashi K; Tatsumi M; Higuchi I; Inoue A; Nakajo K; Ishikawa J; Shimosegawa E; Kanakura Y; Nakamura H; Hatazawa J
Ann Nucl Med; 2008 Nov; 22(9):795-802. PubMed ID: 19039558
[TBL] [Abstract][Full Text] [Related]
14. Imaging: staging and evaluation of lymphoma using nuclear medicine.
Divgi C
Semin Oncol; 2005 Feb; 32(1 Suppl 1):S11-8. PubMed ID: 15786021
[TBL] [Abstract][Full Text] [Related]
15. [Significance of (18)F-FDG-PET/CT for staging and evaluation of therapeutic effect in patient with malignant lymphoma].
Li F; Zhu HY; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Apr; 19(2):523-7. PubMed ID: 21518522
[TBL] [Abstract][Full Text] [Related]
16. PET/CT: appropriate application in lymphoma.
Wang X
Chin Clin Oncol; 2015 Mar; 4(1):4. PubMed ID: 25841711
[TBL] [Abstract][Full Text] [Related]
17. Speeding up PET/MR for cancer staging of children and young adults.
Aghighi M; Pisani LJ; Sun Z; Klenk C; Madnawat H; Fineman SL; Advani R; Von Eyben R; Owen D; Quon A; Moseley M; Daldrup-Link HE
Eur Radiol; 2016 Dec; 26(12):4239-4248. PubMed ID: 27048532
[TBL] [Abstract][Full Text] [Related]
18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
19. Comparison between whole-body MRI with diffusion-weighted imaging and PET/CT in staging newly diagnosed FDG-avid lymphomas.
Albano D; Patti C; La Grutta L; Agnello F; Grassedonio E; Mulè A; Cannizzaro G; Ficola U; Lagalla R; Midiri M; Galia M
Eur J Radiol; 2016 Feb; 85(2):313-8. PubMed ID: 26781135
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography for prostate, bladder, and renal cancer.
Schöder H; Larson SM
Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
